Exiting evidence also indicated that circulating IL-18 was positively associated with insulin resistance, metabolic syndrome (MetS) and type 2 diabetes (10–13), suggesting potential applications of IL-18 as an intervention target or prognostic biomarker. This evidence concerns the gene IL18 and type 2 diabetes mellitus.